{"ticker": {"uuid": "d0f5aa32-f8a9-4e82-af3c-242000942513", "symbol": "BMRN", "name": "BioMarin Pharmaceutical Inc.", "exchange": "MEX", "country": "MX", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "BioMarin stock trades steady as rare disease revenue grows and gene therapy outlook develops", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQbXlqWGQ1NFBLSXBHN1BDa1htMGI0bFVaLUxEMDdTcno0ckZqNEVqM0RpVWRVeFdZR1E0VkJTYVk4ZGhEc0NoNmhZM0VFY3J0YzNYWkFzZXJLWTFHTlZrNVVjekxwZE5nVzRndWhEcXh5TndZSUJFOURDMWpKd1JhQVczb2NOdkdaUDRvMEg5Q2o0b1V1T1prT29tSnczZDVfYTFiYUVaVzVRMG9FUXp4NlZjV2hqVDdwbFdmdF9GOXAyQWFl?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-21T11:50:59+00:00", "published_display": "21 Jul 2026 11:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How FDA Review of VOXZOGO Full-Approval Data at BioMarin (BMRN) Has Changed Its Investment Story", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-17T21:46:17+00:00", "published_display": "17 Jul 2026 21:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZzlFZXljSDNLSjZPTklhMFRRNjg3a0RvT2VVZEJlekdQYk12dklrSE5QV3dvUkc4OG1ialNhNjNnNzJGWnY4RzRxMjJJcmxGX19EcTZ3eDV3S1JkRkJhNkludERTZGZpR1FSVnJXdXJNbndBeXQ3a0VjcG1ydmIxV293QmlYY0N5VnQxVV96bGppZVRLMGk4djNXSnJEXzhLQ28xT1RDTm1kMGc?oc=5", "source_name": "Market source", "published_at": "2026-07-13T22:16:14+00:00", "published_display": "13 Jul 2026 22:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO\u00ae (vosoritide) for Children With Achondroplasia", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwJBVV95cUxQam5XN1B6S1NzSkNIVEZmS01wdVdheThUS3VJS0g5Vy1sNGJta3I5YW95eEZyelJZRXEwcDBhUW1XXzlDNWZOZzN1UTRmVzRpZUtlejJEM2JwODBZalpUcDFPOWRKckRwSjlqX01yMm15bVZyR2tfdzdzRFp4V2IxYUxneU9NVW5HS21LSTNVajFGQmhlR3pPQ0F5ZEplR0g0dkp0cHZhQm1nYjNCbEx3UEx6VFlPclhQcTBoMkxFQURQVHQ4bzRCQU82Y3RpdzUzcUxfN1E2VFc4c0RNb2pvd2RiSUlxQ0M5SHFSM2V0MndIYi1xTDZScVZDQkEyT1Z6MThKallJTndRU1cyemVZWUhTbTI0anFPRWtpNng1ekEwUlR2MFZWR0YtdExlXzlkX3I5LXgtbw?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-13T13:05:00+00:00", "published_display": "13 Jul 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA starts full review of BioMarin\u2019s VOXZOGO for children with achondroplasia", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPNkNYRWJMMnRReklOdjk5YjNxb19iSG5EQVZBNjhGRFp3ZThBZElpLUlyX3RiUXhyZTZVNVE0ZHE0bV9Nc2JQalplZzNSX1JrZkpPMXJRb2pwTjBnRzRGVldiYTFMNVZLR3B5OGxRVXR6VWo4bDlfV3FkRWl4TUhtMlp0OUlEX01abTA2M19DYldDWWRaR0NBN2dkY3U2d1ZHbkc0ckRNQi1QVkoydGxTWW5rVHdsd0lQcDhOdA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T13:05:00+00:00", "published_display": "13 Jul 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPNjRHVUp0bWQ3WUdBN2Q4VGJhVU9sZWdteVJhcElTeHF2am9TZjE4WnFYZFI4RHhSSjdrTDdmckJ3TjU2WTZUMFdJSTZOdFJRVlFkdkctMXZBWkg4OVJZUkFqZ0F4WEJFNFVMODNLTTdpUVA1cGNSY0x3LTZYS0ZpYWpBYUkyY1EtTEcyNl9iUnUzYnJIdnVzaFFkbUFwbmU2MDJEUjc4ZU1kWjJxLXdKdTQ0d2xlWHIyS3hnRVhyRm43elZjUVNQQkVDQnE5S1ZoQ1B3bWlaeVpmbTVtN1E?oc=5", "source_name": "ChartMill", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQWklvMjNjZnd5RXdSRDNYSFYwVkhOTkNGTXFhalg4SVVkWGV6NS1xQmg3OWlzMlI1Q25RR0xRdnhockQ1c1FzbUNWRl9DeE9yWHpMR3haTkxjLXRwUjk0dkktc1VlYmZTSVlwdzYxaFpQRjBQLUdNbklxRnBLTVIxNWdSeXpzYml6dXVLZUJrTFU0YXNMSC1HcHRRdE1VTTQ5RTJN?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Announces New Three-Year VOXZOGO\u00ae (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwJBVV95cUxPMk9MNE9fWE52OFI2MFQ4ay1HZExONVlwM01QcUJQOW5JcXpwS1NlR0pCVE82QWpVcE45ZjZ5dHdEck9oWk9tbHplcjJQZFBuMlVRR1hWRklrNDJqUlJ0OFFfSlRXLWFoSmVVdGdTSXdkVldtNzFITkpCTjlITlcxMkJtdG5yQXJGRlBxUGtFem5RdG80cUstMmpaUjhxRW9Qb3RXTnU1a1RRRXpGWjM2NXpxT2hlYWlDVzJDdEZQN3FuRnMzeGhIekk1NmFySHV4eU9xRWtZVzdpbEVEQTlELTh1TjRhYUdMaWVLclVzWTlBR09WWEUycGpHWTNTX0hMeW1F?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Decent Value Play with Strong Fundamentals", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOTVZBN0VZYzh2ODRqUlJmMzc2ZWYyTndqZjVRRk5vVDdjLVlxOEl2MDVENnBCTjIwNEl4aDBFVld0bFdYTGZNZVNzWmc0dFFrcnhGNV9TQWVOTDN1OEhmcXpsRW5ybHdnUGI4OG5vQTBMUUFIZWNYaTJDS0xmM0dyODZ3dlMzS3FjcE1WNTJNT042NTZqaURmQ2tCdEdDTDAteGtNbW9DTUpQNlFWV3NnM0dZZmZSQXVTVjYzTTYtdlFXeEo4Y0p3T3luWm5kUTRp?oc=5", "source_name": "ChartMill", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxORlg3R29XNml0ZW16dzh3Q0xYSlItTU1qdDQ2X3VGUDNKTmNqUHJIQmFaQS00a0ZCNml2NFdMNHFwQTRMUWpYSnlad1puUDAySkxXZ3gwWWd3X2t3cjhYNl9LMndnVWtoWVc1c0hsSVdkUkoyTzd4TlZMbWxnTGV2a09fN2NmdXBkRTV0VFJDUGpZSFdTNUwtNlZwam5QeE84WFhWSUZWbmxOU0FrSXVz?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQcjdjXzROMG1yd2x2YUZDQjZFMmtjWmtCWVFUTURkSzFiQ01JZnA1b09TeXZoOHVNeTBMSDhscThaVTBhOERZY1FoamJpQ3p6bTNiazFEVGJhdGt3dElGVWxSaDdPVjBZUVo1R2JvTXVxSWhjUVhDSEtMcHpHLVdndVlfMU1PNS1vVkF2WmJMbkM0MHowNVRzNU5sS240ckptbm52WlNR?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports First Quarter 2026 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQaE9PQVp2VzJjOWkza2VZZ25vUGRjY2UzVVkxNTFLeF9GTW1NUURkeXdNZmxIMURicnZZdklFYWtzdWJZQlotSkZMNE95YkdxY2NRb29NcGU2d0dwZ0MzWWhicEFiNnRDZldxZEZNdHdWSWxhQkR2N2dNd19VbzA0VTZTcDB1RGhBU0FESDRjRTdDRWhYQXpSUWJHQUtUVFZkLUpXeVJjbTRIZHBUODNhMFM1YWdqNDVremtWblNManY?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Completes Acquisition of Amicus Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdVlTT1VIM19nY2JWQVN0b1hZSEpRSHRlOWVTaUVkQ2pBeVpwSnZWZnlwcVIwR3VWTkFza2ZSUDF1ZW42NE9zRmk0MUtDWU1iM1RPWlBoanhLQ3RLUmJOeHhwN3ZxYjdQSTFjR3QzRWU2WHktdU85VkRYWmZtUmVheWdJYkItUGdZZTJOcDl0dERETXhsWlZQbThjaWxNVF9CdTZBbk94RDVlTlJ6bVE?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Emerges as a Compelling Value Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNQkRNY0FoR3I2eDNqcEsteFVWNVk3TXl0elZmZXh5VGJ2T1g4d2tGX3ZERWs3VmdMazJtd0w0eXJTY0hsUGdCd1QzWnJHM09QNGdWbkpMd0d4UHJMNEZORDVZbW55ZXpKb0p4UEhjYlRmRXRvVlp5T3ZLYjBFd0xRTGpHang4RzBmVHJrRl9oek14MS03VWNwNmxUQjByMEZUM2txMWxSUXU0d0h2RnFEYzRDbjZva2Y3ZldLa3B2UFM5S21Z?oc=5", "source_name": "ChartMill", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNdFZ6TTl1TXh6Yk5hakNaUEpMS3lyVHdJR25hTVdPREdsSFQ5c1VldEpxTUp3bmc3dXBtU00teFVxdVpjS1QyXzJJNXFtZFgwMUlMRU1nblVzbkpnM0RGRGJuM1VTUHYwTHlyY01LZDRRSHRKNms5TzRQOURkcFB1d2F4b0FGSktxYlZWUEFDU1hIY1FqZlMzVVlMLVFteVdtSjlveGFQcjkyU0RQbEx2Vkd2clBKWmJmcFFYdlFiZFc2NW0tRllOcEtlTW5zbFZyZF9Cbw?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPVzNsNlBZR3RFdXoxdWFPNzNNU3Ftc0Vnc0QzdV9EQi05QVpUZ0J6SExTbnhXci1GNUlObFJqRjQ3QmktMW5DZkxaU0trYWgwa195WDRzYmpJSnFTSkh2NWlEZVZLZEh0OW4zdFZYeXNqdjlmY19Eb1RsUmJSSmVXRzAxRHA4VlRCb1UtZ01veHZONDgtRmpacTFHTzQ3S3lsWW1KSDYzTGdyUmtXRHZmQ2UtZjhhWUF0UmtJRkgzUmRBM245QjhLZw?oc=5", "source_name": "PR Newswire", "published_at": "2025-10-27T07:00:00+00:00", "published_display": "27 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPeExfWGVMWWI4QS1sYVBVaXhvS2hiZzNrOHlTcXUyOXMtbFdKRGQ1ODkwN0l0LUUyWUY3RDY4andpNk1FRnJ5d2xUYkdBY1V3cXh4T1RXSmdmQVBDaUxrVGx4c0o5UjBLaV9Ua0xfY3cxQkZDZ1RPZUJmSy1CaW9SM2Zqd2VsYXJRQ0tneW9YRWc1aEo5Y09qS0tXVkROYjhKeEFTTUk5STNpZkljbTJEbURlaTVyc00wNkxUSl9qemdRYlVYLXlPSmVDWUk4S283cEwteW5LMEh5ejA?oc=5", "source_name": "PR Newswire", "published_at": "2025-02-19T08:00:00+00:00", "published_display": "19 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biomarin Pharmaceutical Stock Price Forecast. Should You Buy BMRN?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE5md2F6WWtqWkhoMjFGMjBCODRmWm51TkV1UU9PTkpMaDJtR010R2w3S1hDNXRXRVNUSW1XbWRmS0J2N3RIMnFSVw?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-01T10:04:05+00:00", "published_display": "01 Dec 2020 10:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "BioMarin stock trades steady as rare disease revenue grows and gene therapy outlook develops", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQbXlqWGQ1NFBLSXBHN1BDa1htMGI0bFVaLUxEMDdTcno0ckZqNEVqM0RpVWRVeFdZR1E0VkJTYVk4ZGhEc0NoNmhZM0VFY3J0YzNYWkFzZXJLWTFHTlZrNVVjekxwZE5nVzRndWhEcXh5TndZSUJFOURDMWpKd1JhQVczb2NOdkdaUDRvMEg5Q2o0b1V1T1prT29tSnczZDVfYTFiYUVaVzVRMG9FUXp4NlZjV2hqVDdwbFdmdF9GOXAyQWFl?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-21T11:50:59+00:00", "published_display": "21 Jul 2026 11:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How FDA Review of VOXZOGO Full-Approval Data at BioMarin (BMRN) Has Changed Its Investment Story", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxPR2dYY2tqSDB2TUVwTmEtQjMtVktxZHFCZ05OSEpSS0xyVXpNOGlycHJfcXF5RzN0eUd4NXgzZS1BZWhNc3VSV2YxSEpyZGRkbExlM0x3SC1nSGVsVXMwekQxNFo3WlBITWtackVCUmI4blBiWm5IdFFseVlPRV9fZnFYWEc1NXllMnRZa294eGpDRVB2LS1SQlhqVXFTcWQ0WGJGRy1GRDY4NTdPNlhUTUlYMW1Cak9zajFNV19qZm1HRFhaQlpaamxfdHQxQ0p3a1VoLXRNdjBUR2djRWVKVW1SUlF2MzlZSVlYbTZR0gHzAUFVX3lxTFA3MkQ3S3RxNzZId1gtRlJ3eF9URnY2MU5mOGdfWjk0c045b1VyV3NmZGd2VEVGamJxZGhDTGdNQUdRbkJOSl84ODRNaGRlNzJzMXZ6R2I1WXpwTk8wMm5OZnhEZFNDeFliTXRsUEU4NThaWkFsS1BXZm9LR2lEYzNRTzJ2Zk84Sm12enI0SGh0RGFNYzRCRW4wQnkxUjd6a3l6dTVJQURjZkhUX3hwZ3FHd2M2aFJSaGdTcXUwZV9BNjA1TkM2enNzaWtMbTBnLXcwNWxONWx0TExubWJTaFJBelhyRk9tUE81XzFZSFRlaF9sZw?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-17T21:46:17+00:00", "published_display": "17 Jul 2026 21:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZzlFZXljSDNLSjZPTklhMFRRNjg3a0RvT2VVZEJlekdQYk12dklrSE5QV3dvUkc4OG1ialNhNjNnNzJGWnY4RzRxMjJJcmxGX19EcTZ3eDV3S1JkRkJhNkludERTZGZpR1FSVnJXdXJNbndBeXQ3a0VjcG1ydmIxV293QmlYY0N5VnQxVV96bGppZVRLMGk4djNXSnJEXzhLQ28xT1RDTm1kMGc?oc=5", "source_name": "Market source", "published_at": "2026-07-13T22:16:14+00:00", "published_display": "13 Jul 2026 22:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO\u00ae (vosoritide) for Children With Achondroplasia", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwJBVV95cUxQam5XN1B6S1NzSkNIVEZmS01wdVdheThUS3VJS0g5Vy1sNGJta3I5YW95eEZyelJZRXEwcDBhUW1XXzlDNWZOZzN1UTRmVzRpZUtlejJEM2JwODBZalpUcDFPOWRKckRwSjlqX01yMm15bVZyR2tfdzdzRFp4V2IxYUxneU9NVW5HS21LSTNVajFGQmhlR3pPQ0F5ZEplR0g0dkp0cHZhQm1nYjNCbEx3UEx6VFlPclhQcTBoMkxFQURQVHQ4bzRCQU82Y3RpdzUzcUxfN1E2VFc4c0RNb2pvd2RiSUlxQ0M5SHFSM2V0MndIYi1xTDZScVZDQkEyT1Z6MThKallJTndRU1cyemVZWUhTbTI0anFPRWtpNng1ekEwUlR2MFZWR0YtdExlXzlkX3I5LXgtbw?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-13T13:05:00+00:00", "published_display": "13 Jul 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA starts full review of BioMarin\u2019s VOXZOGO for children with achondroplasia", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPNkNYRWJMMnRReklOdjk5YjNxb19iSG5EQVZBNjhGRFp3ZThBZElpLUlyX3RiUXhyZTZVNVE0ZHE0bV9Nc2JQalplZzNSX1JrZkpPMXJRb2pwTjBnRzRGVldiYTFMNVZLR3B5OGxRVXR6VWo4bDlfV3FkRWl4TUhtMlp0OUlEX01abTA2M19DYldDWWRaR0NBN2dkY3U2d1ZHbkc0ckRNQi1QVkoydGxTWW5rVHdsd0lQcDhOdA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T13:05:00+00:00", "published_display": "13 Jul 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPNjRHVUp0bWQ3WUdBN2Q4VGJhVU9sZWdteVJhcElTeHF2am9TZjE4WnFYZFI4RHhSSjdrTDdmckJ3TjU2WTZUMFdJSTZOdFJRVlFkdkctMXZBWkg4OVJZUkFqZ0F4WEJFNFVMODNLTTdpUVA1cGNSY0x3LTZYS0ZpYWpBYUkyY1EtTEcyNl9iUnUzYnJIdnVzaFFkbUFwbmU2MDJEUjc4ZU1kWjJxLXdKdTQ0d2xlWHIyS3hnRVhyRm43elZjUVNQQkVDQnE5S1ZoQ1B3bWlaeVpmbTVtN1E?oc=5", "source_name": "ChartMill", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQWklvMjNjZnd5RXdSRDNYSFYwVkhOTkNGTXFhalg4SVVkWGV6NS1xQmg3OWlzMlI1Q25RR0xRdnhockQ1c1FzbUNWRl9DeE9yWHpMR3haTkxjLXRwUjk0dkktc1VlYmZTSVlwdzYxaFpQRjBQLUdNbklxRnBLTVIxNWdSeXpzYml6dXVLZUJrTFU0YXNMSC1HcHRRdE1VTTQ5RTJN?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Announces New Three-Year VOXZOGO\u00ae (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwJBVV95cUxPMk9MNE9fWE52OFI2MFQ4ay1HZExONVlwM01QcUJQOW5JcXpwS1NlR0pCVE82QWpVcE45ZjZ5dHdEck9oWk9tbHplcjJQZFBuMlVRR1hWRklrNDJqUlJ0OFFfSlRXLWFoSmVVdGdTSXdkVldtNzFITkpCTjlITlcxMkJtdG5yQXJGRlBxUGtFem5RdG80cUstMmpaUjhxRW9Qb3RXTnU1a1RRRXpGWjM2NXpxT2hlYWlDVzJDdEZQN3FuRnMzeGhIekk1NmFySHV4eU9xRWtZVzdpbEVEQTlELTh1TjRhYUdMaWVLclVzWTlBR09WWEUycGpHWTNTX0hMeW1F?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Decent Value Play with Strong Fundamentals", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOTVZBN0VZYzh2ODRqUlJmMzc2ZWYyTndqZjVRRk5vVDdjLVlxOEl2MDVENnBCTjIwNEl4aDBFVld0bFdYTGZNZVNzWmc0dFFrcnhGNV9TQWVOTDN1OEhmcXpsRW5ybHdnUGI4OG5vQTBMUUFIZWNYaTJDS0xmM0dyODZ3dlMzS3FjcE1WNTJNT042NTZqaURmQ2tCdEdDTDAteGtNbW9DTUpQNlFWV3NnM0dZZmZSQXVTVjYzTTYtdlFXeEo4Y0p3T3luWm5kUTRp?oc=5", "source_name": "ChartMill", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxORlg3R29XNml0ZW16dzh3Q0xYSlItTU1qdDQ2X3VGUDNKTmNqUHJIQmFaQS00a0ZCNml2NFdMNHFwQTRMUWpYSnlad1puUDAySkxXZ3gwWWd3X2t3cjhYNl9LMndnVWtoWVc1c0hsSVdkUkoyTzd4TlZMbWxnTGV2a09fN2NmdXBkRTV0VFJDUGpZSFdTNUwtNlZwam5QeE84WFhWSUZWbmxOU0FrSXVz?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQcjdjXzROMG1yd2x2YUZDQjZFMmtjWmtCWVFUTURkSzFiQ01JZnA1b09TeXZoOHVNeTBMSDhscThaVTBhOERZY1FoamJpQ3p6bTNiazFEVGJhdGt3dElGVWxSaDdPVjBZUVo1R2JvTXVxSWhjUVhDSEtMcHpHLVdndVlfMU1PNS1vVkF2WmJMbkM0MHowNVRzNU5sS240ckptbm52WlNR?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports First Quarter 2026 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQaE9PQVp2VzJjOWkza2VZZ25vUGRjY2UzVVkxNTFLeF9GTW1NUURkeXdNZmxIMURicnZZdklFYWtzdWJZQlotSkZMNE95YkdxY2NRb29NcGU2d0dwZ0MzWWhicEFiNnRDZldxZEZNdHdWSWxhQkR2N2dNd19VbzA0VTZTcDB1RGhBU0FESDRjRTdDRWhYQXpSUWJHQUtUVFZkLUpXeVJjbTRIZHBUODNhMFM1YWdqNDVremtWblNManY?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Completes Acquisition of Amicus Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdVlTT1VIM19nY2JWQVN0b1hZSEpRSHRlOWVTaUVkQ2pBeVpwSnZWZnlwcVIwR3VWTkFza2ZSUDF1ZW42NE9zRmk0MUtDWU1iM1RPWlBoanhLQ3RLUmJOeHhwN3ZxYjdQSTFjR3QzRWU2WHktdU85VkRYWmZtUmVheWdJYkItUGdZZTJOcDl0dERETXhsWlZQbThjaWxNVF9CdTZBbk94RDVlTlJ6bVE?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Emerges as a Compelling Value Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNQkRNY0FoR3I2eDNqcEsteFVWNVk3TXl0elZmZXh5VGJ2T1g4d2tGX3ZERWs3VmdMazJtd0w0eXJTY0hsUGdCd1QzWnJHM09QNGdWbkpMd0d4UHJMNEZORDVZbW55ZXpKb0p4UEhjYlRmRXRvVlp5T3ZLYjBFd0xRTGpHang4RzBmVHJrRl9oek14MS03VWNwNmxUQjByMEZUM2txMWxSUXU0d0h2RnFEYzRDbjZva2Y3ZldLa3B2UFM5S21Z?oc=5", "source_name": "ChartMill", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNdFZ6TTl1TXh6Yk5hakNaUEpMS3lyVHdJR25hTVdPREdsSFQ5c1VldEpxTUp3bmc3dXBtU00teFVxdVpjS1QyXzJJNXFtZFgwMUlMRU1nblVzbkpnM0RGRGJuM1VTUHYwTHlyY01LZDRRSHRKNms5TzRQOURkcFB1d2F4b0FGSktxYlZWUEFDU1hIY1FqZlMzVVlMLVFteVdtSjlveGFQcjkyU0RQbEx2Vkd2clBKWmJmcFFYdlFiZFc2NW0tRllOcEtlTW5zbFZyZF9Cbw?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPVzNsNlBZR3RFdXoxdWFPNzNNU3Ftc0Vnc0QzdV9EQi05QVpUZ0J6SExTbnhXci1GNUlObFJqRjQ3QmktMW5DZkxaU0trYWgwa195WDRzYmpJSnFTSkh2NWlEZVZLZEh0OW4zdFZYeXNqdjlmY19Eb1RsUmJSSmVXRzAxRHA4VlRCb1UtZ01veHZONDgtRmpacTFHTzQ3S3lsWW1KSDYzTGdyUmtXRHZmQ2UtZjhhWUF0UmtJRkgzUmRBM245QjhLZw?oc=5", "source_name": "PR Newswire", "published_at": "2025-10-27T07:00:00+00:00", "published_display": "27 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPeExfWGVMWWI4QS1sYVBVaXhvS2hiZzNrOHlTcXUyOXMtbFdKRGQ1ODkwN0l0LUUyWUY3RDY4andpNk1FRnJ5d2xUYkdBY1V3cXh4T1RXSmdmQVBDaUxrVGx4c0o5UjBLaV9Ua0xfY3cxQkZDZ1RPZUJmSy1CaW9SM2Zqd2VsYXJRQ0tneW9YRWc1aEo5Y09qS0tXVkROYjhKeEFTTUk5STNpZkljbTJEbURlaTVyc00wNkxUSl9qemdRYlVYLXlPSmVDWUk4S283cEwteW5LMEh5ejA?oc=5", "source_name": "PR Newswire", "published_at": "2025-02-19T08:00:00+00:00", "published_display": "19 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biomarin Pharmaceutical Stock Price Forecast. Should You Buy BMRN?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE5md2F6WWtqWkhoMjFGMjBCODRmWm51TkV1UU9PTkpMaDJtR010R2w3S1hDNXRXRVNUSW1XbWRmS0J2N3RIMnFSVw?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-01T10:04:05+00:00", "published_display": "01 Dec 2020 10:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 75, "total_relevant": 18, "sentiment_summary": {"positive": 4, "negative": 0, "neutral": 14, "score": 53, "total": 18, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 4.4, "count": 8}, {"event": "earnings", "label": "Earnings", "weight": 3.3, "count": 6}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 4, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 959.0, "latest_week": "2026-07-17", "one_week_move": 0.0, "four_week_move": 0.0, "twelve_week_move": -2.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.460645, "market_dynamics_buy_signal": false, "relative_strength": -7.527197, "fair_value_gap": -29.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 8.855, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, +0.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 50, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "PR Newswire", "count": 7}, {"label": "Market source", "count": 4}, {"label": "ChartMill", "count": 3}, {"label": "Ad-hoc-news.de", "count": 1}, {"label": "simplywall.st", "count": 1}, {"label": "Stock Titan", "count": 1}, {"label": "StockInvest.us", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 18}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 8}, {"label": "Earnings", "count": 6}, {"label": "Regulatory and legal", "count": 1}, {"label": "Analyst action", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "18", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.0% over one week, +0.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "BioMarin stock trades steady as rare disease revenue grows and gene therapy outlook develops"}], "updated_at": "2026-07-21T17:53:00.962498+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}